Lucinactant (Surfaxin): synthetic lung coating for premature babies
A lab-made drug that keeps the tiny air sacs in premature babies' lungs from collapsing so they can breathe; FDA-approved to prevent and treat newborn respiratory distress syndrome.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Lucinactant (brand name Surfaxin, developed by Discovery Laboratories) is a synthetic lung surfactant used to prevent and treat respiratory distress syndrome (RDS) in premature infants. Its active ingredient is a 21-amino-acid peptide called sinapultide — also known as KL4 — that mimics the action of human surfactant protein B (SP-B), the small hydrophobic protein in natural lung surfactant that helps the air sacs in the lungs stay open during breathing (Moya 2005; Moen 2005). Before lucinactant, doctors had two imperfect choices for surfactant therapy: animal-derived preparations that contained the real protein but carried supply and contamination concerns, and earlier-generation protein-free synthetic surfactants that lacked the SP-B activity needed to work as well as the animal products (Lal 2008; Pfister 2007). Lucinactant was the first synthetic surfactant designed to recover the protein function using a simple peptide stand-in. The KL4 peptide is a repeating arrangement of single lysines alternating with blocks of four leucines (KLLLLKLLLLKLLLLKLLLLK), formulated together with phospholipids and palmitic acid; the lipid carrier is part of the drug, not just an excipient.
History
Synthetic surfactants without protein had been in clinical use since the early 1990s (Exosurf / colfosceril palmitate), but a head-to-head comparison was needed once a protein-containing synthetic alternative became available (Lal 2008). Early human work with Surfaxin in adults explored bronchopulmonary segmental lavage for acute respiratory distress syndrome (Wiswell 1999). The pivotal multicenter pediatric trial by Moya and colleagues (Pediatrics 2005) compared lucinactant to colfosceril palmitate (protein-free synthetic) and to beractant (animal-derived) for prevention of RDS in very preterm infants. A parallel trial by Sinha and colleagues (Pediatrics 2005) compared lucinactant to poractant alfa, another animal-derived surfactant. Reviews and pharmacoeconomic analyses followed through the late 2000s and early 2010s (Moen 2005; Donn 2005; Piehl 2012; Jordan 2013; Guardia 2012). Lucinactant was approved by the U.S. FDA in March 2012 — the first synthetic peptide-containing surfactant approved for neonatal use — on the basis of a multinational Phase 3 program that included 1,294 patients (Piehl 2012; Jordan 2013). The aerosolized delivery route was also investigated as a less invasive alternative to intratracheal instillation (Donn 2008).
What it does
In premature lungs, the air sacs (alveoli) can collapse on every exhale because there isn't enough natural surfactant to lower surface tension at the air-liquid interface. Lucinactant is instilled into the lungs and spreads as a thin film: the KL4 peptide, embedded in the phospholipid mixture, performs the surface-tension-lowering job that surfactant protein B normally does, helping alveoli stay open and improving gas exchange. In a preterm lamb model of RDS, lucinactant produced acute and sustained improvements in pulmonary gas exchange and lung mechanics comparable to a natural porcine surfactant (Gastiasoro-Cuesta 2006), and in a follow-up preterm lamb study it attenuated pulmonary inflammatory response and preserved lung structure (Wolfson 2012).
Mechanism
KL4 is a cationic, hydrophobic peptide that mimics the lipid-interacting behavior of SP-B. Biophysical studies on model lung-surfactant lipid systems show that KL4 inserts into and reorganizes phospholipid monolayers and bilayers, contributing to the rapid film formation and re-spreading that natural surfactant requires (Ma 1998; Sáenz 2006; Saleem 2008). When bound to POPC:POPG lipid vesicles — a phospholipid composition that approximates the anionic-lipid-enriched environment of surfactant films — KL4 adopts an α-helical conformation (Mills 2008), and the helical structure is functionally important: a later study using modified analogs found that disrupting the α-helix reduces activity in a related application (Qiu 2021). KL4 also showed activity in a more clinically relevant context: it lowered surface tension in the presence of fibrinogen and proteolytic fragments that ordinarily inactivate surfactant — a problem in the diseased lung (Manalo 1996).
Evidence
- Human: In a multicenter randomized masked trial in very preterm infants, lucinactant reduced rates of RDS at 24 hours and RDS-related mortality compared to the protein-free synthetic colfosceril palmitate, and was non-inferior to the animal-derived beractant (Moya 2005). A separate trial directly compared lucinactant to poractant alfa among high-risk very premature infants (Sinha 2005). Cochrane systematic reviews assessed the evidence base for protein-containing synthetic surfactants versus protein-free synthetics (Pfister 2009) and versus animal-derived extracts (Pfister 2007; Ardell 2015). An earlier exploratory adult trial used Surfaxin via bronchopulmonary segmental lavage in ARDS (Wiswell 1999).
- Animal: In a preterm lamb model of RDS, lucinactant produced acute and sustained improvements in gas exchange and pulmonary mechanics comparable to porcine surfactant (Gastiasoro-Cuesta 2006), and attenuated pulmonary inflammation while preserving lung structure (Wolfson 2012). In rats exposed to cigarette smoke, Surfaxin attenuated PM2.5-induced airway inflammation and restored surfactant proteins (Sun 2022).
- In vitro / biophysical: KL4 inserts into surfactant-like lipid monolayers and bilayers, adopts α-helical structure on POPC:POPG vesicles, and recovers surface activity in the presence of fibrinogen-derived inactivators (Ma 1998; Manalo 1996; Sáenz 2006; Saleem 2008; Mills 2008).
Known effects
- Prevention and treatment of neonatal RDS — Phase III (Moya 2005; Sinha 2005)
- Improved pulmonary gas exchange in preterm lungs — Preclinical and clinical (Gastiasoro-Cuesta 2006; Moya 2005)
- Attenuation of pulmonary inflammation — Preclinical, preterm lamb model (Wolfson 2012)
- Acute respiratory distress syndrome (ARDS) in adults via lavage — Early-phase human safety/tolerability only (Wiswell 1999)
- Carrier for inhaled siRNA delivery — Preclinical, exploratory (Qiu 2017; Qiu 2021)
Regulatory status
- US: Approved by the FDA on March 6, 2012, for the prevention of RDS in premature infants at high risk, under the trade name Surfaxin (intratracheal suspension) — the first synthetic peptide-containing surfactant approved by the FDA (Piehl 2012; Jordan 2013). Commercial supply of Surfaxin in the United States was subsequently discontinued by the manufacturer for business reasons rather than safety, efficacy, or quality concerns; the underlying KL4 platform has continued as the basis for aerosolized formulations (Donn 2008).
- EU: Not approved under this indication at the time of the primary clinical reports cited above.
- WADA: Not on the prohibited list.
Aerosolized and follow-on development
A non-invasive aerosolized lucinactant was investigated as a potential alternative to intratracheal surfactant replacement therapy, with the goal of avoiding intubation and its complications in preterm infants (Donn 2008). The same KL4 peptide has also been repurposed outside its original indication: groups have explored KL4 as a vector for pulmonary delivery of small interfering RNA (siRNA), exploiting its ability to associate with anionic cargo and cross lung epithelial cells (Qiu 2017), and modified or PEGylated KL4 variants have been developed to improve tolerance and preserve the α-helical structure that the activity depends on (Qiu 2021 Nucleic Acid Therapeutics; Qiu 2021 Molecular Pharmaceutics).
Safety signals
Reported in the clinical literature, not as guidance. Surfactant administration in preterm infants — across all products — is associated with transient airway events during the instillation procedure itself (reflux, transient desaturation, bradycardia); the comparative trials assessed these alongside efficacy endpoints rather than excluding them (Moya 2005; Sinha 2005). A pharmacoeconomic analysis of in-hospital reintubation rates and costs compared lucinactant with beractant and poractant alfa in preterm infants treated for or at risk of RDS (Guardia 2012). Earlier-generation protein-free synthetics had been associated with excess mortality compared to animal-derived products, which was part of the original rationale for developing a protein-containing synthetic alternative (Sinha 2005; Lal 2008). For ARDS-stage adult use, only early safety and tolerability data exist (Wiswell 1999).
Related peptides
The KL4 peptide is unusual on this platform — it is not a hormone analog or a signaling peptide but a structural mimic of a hydrophobic lung protein. Direct platform analogs are limited; the closest conceptual neighbors are other engineered structural mimetics rather than other surfactant peptides.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does the KLLLL repeat length match the thickness of lung surfactant lipid layers?
If true, drug developers could design new lung surfactant mimics by simply adjusting the leucine block length to match different membrane types. This could help premature babies and possibly adults with acute lung injury who need better synthetic surfactants.
Does this peptide keep lung lining from being squeezed away when we breathe out?
If true, we would understand exactly when and how the peptide helps during the breathing cycle. This could lead to better surfactant drugs that work at lower doses, which would be cheaper and easier to make.
Could this peptide help make lung surfactant drugs that do not need refrigeration?
If true, premature babies in places without reliable refrigeration could still get life-saving surfactant therapy. This could save lives in rural hospitals and developing countries where cold storage is difficult.
Does this peptide stay in the lungs because it cannot dissolve in blood?
If true, this would explain why the drug is safe for tiny premature babies: it stays where it is put. It would also mean any future drugs built from this peptide should only be given by inhalation, not by injection.
Could this peptide be modified to deliver drugs directly to the lungs?
If true, patients with lung diseases could inhale medicines that stay in the lungs instead of spreading through the whole body. This could mean fewer side effects and better treatment for conditions like pneumonia or cystic fibrosis.
▸3-letter notation
▸citationbibtex
@peptide{pep04427,
sequence = {KLLLLKLLLLKLLLLKLLLLK},
target = {},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}